Good Profile of Efficacy/Tolerance of Bortezomib or Idelalisib in Waldenström Macroglobulinemia Associated with Acquired Von Willebrand Syndrome

References

• Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood. 2011;117(25):6777–6785. doi:10.1182/blood-2010-11-29758021540459
   PubMed Web of Science ®Google Scholar
• Treon SP. How I treat waldenström macroglobulinemia. Blood. 2015;126(6):721–732. doi:10.1182/blood-2015-01-55397426002963
   PubMed Web of Science ®Google Scholar
• Mayerhofer M, Haushofer A, Kyrle PA, et al. Mechanisms underlying acquired von Willebrand syndrome associated with an IgM paraprotein. Eur J Clin Invest. 2009;39:833–836. doi:10.1111/eci.2009.39.issue-919572993
   PubMed Web of Science ®Google Scholar
• Gertz MA. Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. Am J Hematol. 2019;94(2):266–276. doi:10.1002/ajh.v94.230328142
   PubMed Web of Science ®Google Scholar
• Ojeda-Uribe M, Caron C, Itzhar-Baikian N, Debliquis A. Bortezomib effectiveness in one patient with acquired von Willebrand syndrome associated to monoclonal gammopathy of undetermined significance. Am J Hematol. 2010;85(5):396.20425807
   PubMed Web of Science ®Google Scholar
• Durand CA, Hartvigsen K, Fogelstrand L, et al. Phosphoinositide 3-kinase p110δ regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol. 2009;183(9):5673–5684. doi:10.4049/jimmunol.090043219843950
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–1018. doi:10.1056/NEJMoa131458324450858
   PubMed Web of Science ®Google Scholar
• Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-hodgkin lymphoma. Blood. 2014;123(22):3406–3413. doi:10.1182/blood-2013-11-53854624615776
   PubMed Web of Science ®Google Scholar
• Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014;124(26):3991–3995. doi:10.1182/blood-2014-06-58329425305202
   PubMed Web of Science ®Google Scholar
• Fidalgo T, Ferreira G, Oliveira AC, et al. Acquired von Willebrand syndrome in haematologic malignancies–how the clinical-laboratory correlation improves a challenging diagnosis–a case series. Haemophilia. 2017;23(4):e361–e365. doi:10.1111/hae.2017.23.issue-428497886
   PubMed Web of Science ®Google Scholar
• Federici AB. Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg? J Thromb Haemost. 2008;6:565. doi:10.1111/j.1538-7836.2008.02917.x18221357
   PubMed Web of Science ®Google Scholar
• Tiede A, Priesack J, Werwitzke S, et al. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost. 2008;6:569–576. doi:10.1111/j.1538-7836.2008.02909.x18208537
   PubMed Web of Science ®Google Scholar
• Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4:2103–2114. doi:10.1111/jth.2006.4.issue-1016889557
   PubMed Web of Science ®Google Scholar
• Available from: https://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/velcade_cpm.pdf. Accessed 129, 2020.
   Google Scholar
• Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27(23):3830. doi:10.1200/JCO.2008.20.467719506160
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Am J Hematol. 2010;85(9):670–674. doi:10.1002/ajh.2178820652865
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Gustine JN, Meid K, et al. Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity. Leuk Lymphoma. 2017;58(4):1002–1004. doi:10.1080/10428194.2016.122238027562445
   PubMed Web of Science ®Google Scholar
• de Weerdt I, Koopmans SM, Kater AP, van Gelder M. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica. 2017;102(10):1629–1639. doi:10.3324/haematol.2017.16410328775119
   PubMed Web of Science ®Google Scholar
• D’Aveni-Piney M, Divoux M, Busby-Venner H, Muller M, Broséus J, Feugier P. Idelalisib in a patient with refractory Waldenström’s macroglobulinemia complicated by anuric renal failure: a case report. J Med Case Rep. 2018;12(1):164. doi:10.1186/s13256-018-1694-z29890999
   PubMedGoogle Scholar
• Treon SP, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia. J Clin Oncol. 2018;36(27):2755–2761. doi:10.1200/JCO.2018.78.642630044692
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia. N Engl J Med. 2018;378(25):2399–2410. doi:10.1056/NEJMoa180291729856685
   PubMed Web of Science ®Google Scholar
• Treon SP, Meid K, Gustine J, et al. Ibrutinib monotherapy produces long-term disease control in previously treated Waldenstrom Macroglobulinemia. Final report of the pivotal trial (NCT01614821). Hematol Oncol. 2019;37(S2):184–185. doi:10.1002/hon.141_2629
   Google Scholar
• Sklavenitis-Pistofidis R, Capelletti M, Liu CJ et al. Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018;132(24):2608-2612.
   Web of Science ®Google Scholar